descending aorta and inferior vena cava, respectivelv. The fetal
The cardiovascular and respiratory effects of the naturally occurring endogenous opiate, methionine-enkephalin, were studied in 23 fetal sheep, five newborn lambs, 15 pregnant sheep, and four nonpregnant ewes. The opiate peptide produced dose-dependent decreases in heart rate and blood pressure in fetal and neonatal lambs but increased heart rate and blood pressure followed immediately by decreased heart rate and blood pressure in pregnant ewes. The circulatory responses were examined by pharmacologic blockade of receptor activity and by vagotomy. The bradycardia and hypotension in the fetus and tachycardia and hypertension in the adult were shown to be mediated by autonomic efferent nerves. Sinoaortic denervation did not affect the fetal responses to infused enkephalin. Respiration decreased in fetal as well as postnatal animals even at doses of methionine-enkephalin that did not significantly affect heart rate and blood pressure. These data indicate that the cardiovascular effects of infused enkephalins undergo maturational changes and are mediated by the autonomic nervous system.
Endorphins and enkephalins are widely distributed throughout the brain, spinal cord, and peripheral autonomic nervous system (13, 37). Opioid receptors are located in these same areas, but are particularly abundant in regions associated with pain perception and pituitary hormone release (10, 34, 35) and in the medullary nuclei concerned with cardiopulmonary regulation (10, 14, 34, 35) . Opiate receptors also increase both in number and in affinity during the latter third of gestation and in the first few weeks after birth in rats (8, 9, 33) . Because endogenous opiates, such as enkephalin, can modify cardiovascular and pulmonary function in adults (2, 5, 25, 36) , we wished to assess whether there were developmental changes in circulatory regulation by endogenous opiates.
To do this, we chose methionine-enkephalin as an opiate receptor agonist because it has been detected in high concentrations in the adrenal medulla (17, 44) , is secreted into the circulation after appropriate stimulation (16, 39, 41) , and is found widely distributed in autonomic ganglia (19, 30, 37) . In addition, because it is known that the autonomic nervous system matures postnatally (I, 3, 28) , and that the enkephalins may function as cotransmitters with acetylcholine and catecholamines in autonomic ganglia and the adrenal medulla (18, 41) , it is possible that maturational changes in the enkephalinergic system occur and may be important in modifying the cardiovascular response to stress.
MATERIALS AND METHODS
Surgery. Surgery was performed in 25 time-dated pregnant ewes at 120-130 days gestation (term is 145 + 5 days). Lower body anesthesia was accomplished by epidural injection of 2% tetracaine hydrochloride (Winthrop Laboratories, CA). The uterus was exposed through a midline incision and fetal hind limbs were delivered through a small hysterotomy. Polyvinyl catheters were inserted into both pedal arteries and veins and advanced to the catheters \;ere exteriorized at the flank of the kwe a n i stored in a cloth pouch sewn to the skin. Silver electrodes were sewn subcutaneously on the fetal chest and were used to monitor the fetal electrocardiogram. A tracheal catheter was inserted in most fetuses to monitor fetal intrauterine respiratory movements. Catheters were also inserted into a maternal artery and vein at the time of surgery. Three newborn lambs and four nonpregnant ewes had arterial and venous catheters placed under local anesthesia with 1% lidocaine hydrochloride (Cutter Laboratories, Berkeley, CA). Fetuses and ewes were studied from 1-7 days, and neonatal lambs from 1 day through 4 wk after surgery. Arterial pH, PC02, PO?, and hemoglobin were normal in all animals at the time of study and were determined on a Radiometer Blood Gas Analyzer (Copenhagen, Denmark). Heart rate was recorded continuously with a Beckman &channel recorder (Schiller Park, IL) and was derived from the aortic pressure signal recorded from a Statham P23Db pressure transducer (Oxnard, CA). Mean aortic pressure was derived from electrical damping of the phasic pressure tracing and recorded simultaneouslv on a separate channel.
Protocol. After a suitable baseline^ recording of heart rate and " blood pressure was obtained ( 2 3 min, e.g., last 30 sec illustrated in Fig. I ), uniform doses of methionine-enkephalin (Sigma Chemical Co., St. Louis, MO) were injected into both fetuses (weight, 2-3 kg, and 120-130 days gestation) and newborn lambs (weight, 5-8 kg and age, 2-4 wk) in various amounts (0.3, 3, 5, 10, 15, 30, and 300 nmole, in random order; range, 0.1-150 nmole/kg). To study adult female animals (weight, 45-55 kg) a dose of 3000 nmole (range, 55-65 nmole/kg) was given because it was apparent after initial experiments that lower amounts did not affect the variables measured and that the weight-specific dose range was narrow. Later, when examining mechanisms at various ages, we gave a single, weight-specific dose chosen to produce an obvious and significant cardiovascular response, but a response of short duration ( 5 1 min). This was accomplished with a dose of approximately 15 nmole/kg (30 nmole) in fetal and neonatal animals and with a dose of approximately 50 nmole/kg in adult animals. In adult animals, a dose of 3000 nM was given because the lower amounts did not affect the variables measured. The peptide was dissolved in I ml of 0.9% NaCl solution and administered through the venous catheter. Heart rate and blood pressure were allowed to return to control values for 3-5 min before a second dose was given. The mechanism of the heart rate and blood pressure responses to methionine-enkephalin in the ewe was also examined by preferential pharmacologic blockade of autonomic receptors. Specifically, muscarinic receptors were blocked with atropine ( 15-20 mg, Methionine-enkephalin causes opposite effects on heart rate and mean aortic blood pressure in the fetus at 0.8 gestation (n = 5) when compared to the pregnant adult (n = 5). Asrerisks indicate the first heart rate or blood pressure values different from control by Scheffe's multiple contrasts test (i * S.E., P < 0.05).
IV) and propranolol (Ayerst Laboratories, New York, NY, 10 mg, IV) was used to block beta-adrenergic receptors. Alpha-adrenergic receptor blockade was accomplished with either phenoxybenzamine (Smith, Kline, and French, Philadelphia, PA, I mg/kg, IV) or phentolamine (Ciba Pharmaceutical Co., Summit, NJ, 10 mg, IV). Two alpha-adrenergic receptor antagonists were used in an attempt to test for and limit the possible interaction between the opiate system and central alpha? receptor regulation of the circulation (1 1,24). Phenoxybenzamine and phentolamine were chosen because they block both presynaptic (alpha,) and postsynaptic (alpha2) receptors by independent and unequal mechanisms (42) . They also have unequal effects at these receptors and on central regulation of brainstem reflexes (22, 42) . Thus, if we could eliminate the vasopressor response to 200 pg of intravenous phenylephrine (alphal-agonist) (Winthrop Laboratories, New York, NY) and thereby demonstrate equivalence peripherally, any differences that occurred would suggest central alpha?-opiate receptor interactions, which could override the weaker alpha2 antagonist effects of these drugs. Effective beta-adrenergic receptor blockade was demonstrated by the lack of a heart rate response to isoproterenol (Elkins-Sinn, Inc., Cherry Hill, NJ, 0.05 pg/kg, IV).
Statistical methods. Continuous data were tabulated from instantaneous values of heart rate and mean aortic blood pressure and were analyzed statistically by one-way analysis of variance with repeated measures. If the analysis of variance indicated a significant event had occurred, the Scheffe multiple contrast test was employed to compare the mean values of the sequentially tabulated variables (at the designated times after injection, e.g., Fig. l) , to the baseline period recordings taken as one group. The Scheffe test is an a priori statistical procedure that uniquely suited for grouping baseline data in this way (45) . The Scheffe test also provides the greatest strength in analyzing continuous data after an analysis of variance procedure demonstrates a significant event has occurred because it is less likely than other similar tests to falsely identify a difference that does not exist (45) .
RESULTS
Methionine-enkephalin, in doses of 3 nM reduced fetal heart rate in most animals but a statistically significant reduction in heart rate and blood pressure was achieved only at doses greater than 10 nM. There was a dose response relationship between fetal heart rate and methionine-enkephalin with the maximal decrease of heart rate (56% reduction from control) occurring at the 300 nM (approximately 150 nM/kg) dose (179 + 4 S.E. bpm to 79 + 5 S.E. bpm n = 4, P < 0.01, Scheffi's test) lasting for 10-15 sec (Table I) . There was also a dose-dependent relationship with mean arterial pressure, which fell 3 1% after 300 nM of methionineenkephalin (42.7 + 2.3 S.E. mmHg to 24.8 f 6.1 S.E. mmHg, n = 4, P < 0.05, Scheffi's test). The blood pressure reduction followed the decrease in fetal heart rate and both heart rate and blood pressure returned to control values within I min after administration of the peptide at all doses used (Fig. 1) . Repeat doses of methionine-enkephalin given within 10 sec of the peak heart rate response (e.g., at 25-35 sec after initial dose) showed tachyphylaxis and caused no further change in fetal heart rate or pressure; however, repeat doses after this period but before full recovery usually produced an additional and equivalent heart rate response. No changes in electrical conduction in the heart were noted on the electrocardiogram after the infusion of the drug. This indicated that the bradycardia was sinus in origin (Fig. 2) .
The average peak reduction in fetal heart rate at the 30 nM dose of methionine-enkephalin (approximately 15 nM/kg) was 47% (n = 5, P < 0.002, Scheffk's test, Fig. I and Table 1 ). This dose was used in subsequent studies to test the mechanism of the fetal bradycardia. Newborn lambs (n = 5), studied serially up to 4 wk after birth, showed similar directional changes in heart rate and blood pressure as the fetus.
Adult sheep did not respond until a dose of 3000 nM of methionine-enkephalin was given. No other doses between 300 nM (6 nM/kg) and 3000 nM (60 nM/kg) were used. In contrast to the fetal and newborn lambs (Table 3, in pregnant ewes there was an initial increase in heart rate (98 + 6 S.E. bpm, to 119 + 7 S.E. bpm, n = 5, P < 0.001, Scheffi's test) and mean arterial blood pressure (83.4 + 2.5 S.E. + mmHg, to 103.2 + 5.9 S.E. mmHg, n = 5, P < 0.001, Scheffe's test) followed by bradycardia and hypotension (Fig. 1) . Both the heart rate and blood pressure responses returned to control levels by 1 min after the injection. ~l i h o u~h vascular reactivity to other-nonopiate vasoactive peptides differs between pregnant and nonpregnant animals (43), we did not observe any difference in blood pressure response to methionine-enkephalin in pregnant and nonpregnant ewes (Table  2) , but in the nonpregnant animals the heart rate did not increase significantly ( Table 2) . In pregnant ewes given 3000 nM of methionine-enkephalin, fetuses did not show responses in heart rate or blood pressure. Also, no cardiovascular responses were noted in the twin fetus when its mate received up to 300 nM of methionine-enkephalin. Enkephalins either do not cross the placental barrier or are rapidly catabolized by the placenta. The mechanism of the fetal bradycardia was tested using a 30 nM dose of methionine-enkephalin before and after pharmacologic blockade in 15 animals studied separately. The heart rate response was effectively blocked by atropine, trimethaphan, and vagotomy (Fig. 3) ; however, naloxone in doses of 1 mg/kg diminished the heart rate and blood pressure responses to methionine-enkephalin (Fig. 2) , but a dose of 3 mg/ kg was needed to abolish them (n = 4). Sinoaortic denervation did not alter the heart rate or blood pressure responses (n = 5) ( Table 2 ).
The mechanisms of the increased heart rate and blood pressure responses in the adult ewe were also examined by preferential pharmacologic blockade of autonomic receptors. The initial tachycardia was prevented by beta-adrenergic receptor blockade (propranolol) without affecting the pressor response (n = 4).
Data from alpha adrenergic receptor blockade with phenoxybenzamine (n = 3) or phentolamine (n = 3) were analyzed separately. Due to the small number of animals in each group, data frgm respective baseline periods were compared to the corresponding paired group of values obtained at the time of maximal response (e.g., from 12.5-27.5 sec as previously determined in untreated animals, Fig. 1) . In ewes pretreated with phenoxybenzamine, methionine-enkephalin decreased heart rate from 122 + 18 S.E. bpm to 95 + 19 S.E. bpm (P < 0.001, Scheffk's test) and decreased mean aortic pressure from 77.9 + 3.3 S.E. mmHg to 69.2 k 6.4 S.E. mmHg (not significant). Phentolamine had a similar, effect decreasing heart rate from 187 f 4 S.E. bpm to 152 k 27 S.E. bpm (P < 0.02) and decreasing mean aortic pressure from 103.7 + 4.3 S.E. mmHg to 102.7 k 6.1 S.E. mmHg (not significant). These changes in heart rate and blood pressure were abolished by atropine when examined in a single animal from each group.
In five fetuses, intrauterine respiratory movements were abolished immediately (less than 5 sec) after injection of methionineenkephalin in low doses that did not significantly affect heart rate or blood pressure (Fig. 4A) . In contrast, 0.9% NaCl solution had no consistent effects on resuiration in these animals. Similarly, the depth and frequency of ;espiration immediately decreased or aonea occurred for uv to 30 sec after methionine-enkevhalin in L the three ewes and three lambs studied in a similar way (Fig. 4B) . ' HR, heart rate and MAP, mean aterial pressure.
11 P < 0 . 0 5 ,~P < 0 . 0 2 , $ P < 0 . 0 1 , * P < 0 . 0 0 2 ,~P < 0 . 0 0 1 .
DISCUSSION
These data indicate that fetal and newborn lambs respond to methionine-enkephalin with bradycardia and resulting hypotension that is mediated by increased activity of vagal efferent nerves consistent with the suggested central site of action for leucineenkephalin, methionine-enkephalin (2, 5, 25, 36) , and other nonpeptide opiate drugs (26, 27) in several species.
The increased heart rate and blood pressure that occurs in the ewe after methionine-enkephalin is similar to that reported when administered centrally or peripherally (2, 5, 25, 36) ; the effects can be modified or eliminated by autonomic receptor blockade. The responses in the sheep fetus are quite different in that bradycardia and hypotension are induced by methionine-enkephalin. The bradycardia is blocked by atropine, indicating it is vagally-mediated. Our studies indicate that the cardiovascular effects of infused methionine-enkephalin are mediated by the autonomic nervous system and that the effects develop to maturity in sheep older than 4 wk of age. Animals of all ages responded with a decrease in respiratory frequency, suggesting that there is a difference in the developmental pattern in the pathways and receptors mediating the peptide's respiratory and cardiovascular effects.
It has been suggested that the opiate receptors, which mediate
BEFORE AFTER BEFORE AFTER BEFORE AFTER BEFORE AFTER Fig. 3 . Peak fetal heart rate responses as % of control following 30 nM (15 nM/kg) of methionine-enkephalin (hatched areas) before and after selective pharmacologic blockade (% + S.E.). Control heart rate was 176 f 3 S.D. (n = 15). Data were analyzed by paired r test. All heart rate . . responses to methionine-enkephalin before manipulation were significantly different from control values (P < 0.002, paired i test). See text for details.
the analgesic and respiratory effects of opiates (33, 40) , undergo developmental changes in number and affinity during the postnatal period (8, 9, 10, 46) . Subpopulations of opiate receptors (e.g., mu, delta, kappa, sigma) (27,29,3 1) may also show developmen<al changes but this possibility has yet to be examined. On the other hand, because methionine-enkephalin is estimated to be eight times more potent in delta opiate receptor assays than it is in mu receptor assays (29) , it is thought to preferentially stimulate deltatype opiate receptors on an equimolar basis. It would be appealing to suggest that the maturational effects we now describe are due to deficiencies in fetal delta opiate receptors because preferential mu receptor stimulation (with morphine) produces bradycardia and hypotension (3 1). This hypothesis will require further proof.
Alternatively, the difference between the perinatal and adult responses to methionine-enkephalin may be attributed to the maturation of the blood-brain barrier in the perinatal period. This is unlikely for several reasons. In the sheep, the blood-brain barrier is effectively present by 125 days gestation (6) . In adults animals, it is absent in the region of the area postrema (7) where endogenous opiate receptors (10, 14, 34, 35) and the autonomic nuclei of the brainstem are located. The barrier is also absent in parts of the hypothalamus (7) . Because the brainstem (area postrema) and hypothalamus are both involved with central autonomic circulatdry controls, they are important as potential sites of action for circulating opiate peptides. For example, the region of the area postrema is thought to be the site of action for another circulating peptide, the octopeptide angiotensin I1 (12) (rnethionine-enkephalin is a pentapeptide). Finally, even if there were a blood-brain barrier present in the region where the opiates .act, methionine-enkephalin has been shown to cross the blood-brain barrier in rats at rates fast enough (less than 5 sec) to account for a central cardiovascular effect (21) .
Stimulation of the afferent limb of cardiovascular reflexes (e.g., baroreflex or chemoreflex) may also be the mechanism by which rnethionine-enkephalin acts in the fetus. The presence of a similar opiate effect on heart rate and blood pressure in sinoaortic denervated fetuses again implicates a central site of action for the infused peptides. We did not study other cardiovascular reflexes that can produce bradycardia and apnea when activated; therefore, we cannot eliminate stimulation of the Bezold-Jarisch reflex (coronary chemoreflex) or the pulmonary J receptor reflex in explaining the fetal and neonatal lamb's response to methionine-enkephalin. On the other hand, the ewe's response to methionine-enkephalin is exactly opposite to both the expected response of the coronary chemoreflex to veratridine ( I ) and to chemostimulation of pulmonary J receptors. (Leji handpanel), recordings of mean aortic blood pressure, heart rate, and tracheal pressure in a fetal lamb (125 days gestation) that received I0 nM of methionine-enkephalin during a period of respiratory activity. Note the prompt cessation of respiratory motion and the absence of a significant effect on fetal heart rate. Timing marks: one/sec, long mark indicates minute elapsed. (Right hand panel), recordings of mean aortic blood pressure, heart rate, and tracheal pressure in a fetus at 125 day gestation in a 2-wk-old lamb, and in a pregnant ewe. Respiratory excursions are displayed with heart rate and blood pressure. Note the distinct change in respiratory activity, independent of the timing of the circulatory effects, in response to methionine-enkephalin (fetus and lamb, 15 nanomole/kg; ewe 50 nanomole/kg). maturational effects we describe, it appears that the cardiovascular effects of intravenous methionine-enkephalin in sheep result from its direct action on central autonomic centers and not from receptor stimulation in peripheral cardiovascular reflexes.
The unexpected vagal bradycardia and hypotension after infusion of this peptide in ewes treated acutely with either phenoxybenzamine or phentolamine is intriguing. These results may simply indicate a sensitization to the hypotensive and bradycardic effects of opioid drugs due to an inability for compensatory vasoconstriction to occur under these conditions (42) or may be evidence of more subtle interactions in central autonomic centers. For example, central alphaz receptor agonists produce bradycardia and hypotension (4, 42) . Because we did not test for the effectiveness of the alpha? antagonism achieved, our data may indicate that these peptides have alpha2 agonist activity ( I 1, 24) , which can override partial alpha? receptor antagonism; however, we did not observe these effects after any other manipulation, thus making this an unlikely possibility. Alternatively, it has been shown that phenoxybenzamine increases binding of [3H] morphine to central opiate receptors in vivo (38) and by this mechanism central alpha, antagonists may actually enhance binding of methionine-enkephalin to these same receptors. In this fashion, methionine-enkephalin could conceivably become a preferential agonist at opiate receptors, which preferentially bind morphine and thereby cause bradycardia and hypotension as well.
Methionine-enkephalin is found in autonomic ganglia (19, 30, 37) , in the adrenal medulla (17, 44) , and in brain stem nuclei concerned with cardiopulmonary regulation (10, 14, 34, 35) . Our identification of maturational changes in the autonomic nervous system's response to methionine-enkephalin may be yet another important factor to consider in understanding the postnatal maturation of the autonomic nervous system (1, 3) as well as the pathophysiology of perinatal syndromes associated with autonomic nervous system imbalance, such as neonatal apnea (23) . In support of this hypothesis, is evidence that naloxone can stimulate fetal and neonatal respiratory activity (15, 20, 32) and our evidence that naloxone also antagonizes the circulatory effects of methionine-enkephalin.
